MCID: SYS067
MIFTS: 20

Systemic Lupus Erythematosus 15

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Immune diseases, Bone diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus 15

MalaCards integrated aliases for Systemic Lupus Erythematosus 15:

Name: Systemic Lupus Erythematosus 15 54
Systemic Lupus Erythematosus, Susceptibility to, 15 13

Classifications:



External Ids:

OMIM 54 300809

Summaries for Systemic Lupus Erythematosus 15

MalaCards based summary : Systemic Lupus Erythematosus 15, also known as systemic lupus erythematosus, susceptibility to, 15, is related to barth syndrome. An important gene associated with Systemic Lupus Erythematosus 15 is SLEB15 (Systemic Lupus Erthematosus, Susceptibility To, 15). The drugs Simvastatin and Anticholesteremic Agents have been mentioned in the context of this disorder. Affiliated tissues include t cells, monocytes and skin.

Description from OMIM: 300809

Related Diseases for Systemic Lupus Erythematosus 15

Symptoms & Phenotypes for Systemic Lupus Erythematosus 15

Clinical features from OMIM:

300809

Drugs & Therapeutics for Systemic Lupus Erythematosus 15

Drugs for Systemic Lupus Erythematosus 15 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 115)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4 79902-63-9 54454
2 Anticholesteremic Agents Phase 4,Phase 1,Phase 2
3 Antimetabolites Phase 4,Phase 2,Phase 1
4 Calcium, Dietary Phase 4,Phase 1,Phase 2
5 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 1,Phase 2
6 Hypolipidemic Agents Phase 4,Phase 1,Phase 2
7 Lipid Regulating Agents Phase 4,Phase 1,Phase 2
8 Rosuvastatin Calcium Phase 4 147098-20-2
9 Hormone Antagonists Phase 4,Phase 2,Phase 3
10 Hormones Phase 4,Phase 2,Phase 3
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
12 Estrogens Phase 4
13 Estrogens, Conjugated (USP) Phase 4
14 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
15 Adrenocorticotropic Hormone Phase 4
16 beta-endorphin Phase 4
17 Melanocyte-Stimulating Hormones Phase 4
18
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
19
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
20
Diphenhydramine Approved Phase 2, Phase 3 58-73-1, 147-24-0 3100
21
Histamine Approved, Investigational Phase 2, Phase 3 75614-87-8, 51-45-6 774
22
Promethazine Approved Phase 2, Phase 3 60-87-7 4927
23
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
24 Antiemetics Phase 2, Phase 3
25 Anti-Inflammatory Agents Phase 2, Phase 3
26 Antineoplastic Agents, Hormonal Phase 2, Phase 3
27 Antirheumatic Agents Phase 2, Phase 3,Phase 1
28 Autonomic Agents Phase 2, Phase 3
29 Dermatologic Agents Phase 2, Phase 3
30 Gastrointestinal Agents Phase 2, Phase 3
31 glucocorticoids Phase 2, Phase 3
32 Peripheral Nervous System Agents Phase 2, Phase 3
33 Analgesics Phase 2, Phase 3
34 Analgesics, Non-Narcotic Phase 2, Phase 3
35 Anesthetics Phase 2, Phase 3
36 Anesthetics, Local Phase 2, Phase 3
37 Anti-Allergic Agents Phase 2, Phase 3,Phase 1
38 Antipruritics Phase 2, Phase 3
39 Antipyretics Phase 2, Phase 3
40 Central Nervous System Depressants Phase 2, Phase 3
41 Histamine Antagonists Phase 2, Phase 3
42 Histamine H1 Antagonists Phase 2, Phase 3
43
Histamine Phosphate Phase 2, Phase 3 51-74-1 65513
44 Hypnotics and Sedatives Phase 2, Phase 3
45 Pharmaceutical Solutions Phase 3,Phase 1
46 Antibodies Phase 3,Phase 2,Phase 1
47 Immunoglobulins Phase 3,Phase 2,Phase 1
48
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
49
Lenograstim Approved Phase 2 135968-09-1
50
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741

Interventional clinical trials:

(show all 43)

id Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
3 Acthar SLE (Systemic Lupus Erythematosus) Recruiting NCT02779153 Phase 4 Acthar low dose (40 U);Acthar high dose (80 U)
4 The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients Withdrawn NCT01359826 Phase 4 Milnacipran
5 A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus Completed NCT00137969 Phase 2, Phase 3 Rituximab;Placebo;Prednisone;Acetaminophen;Diphenhydramine
6 Study of LJP 394 in Lupus Patients With History of Renal Disease Terminated NCT00089804 Phase 3 abetimus sodium (LJP 394) and/or placebo solution;abetimus sodium (LJP 394);Phosphate-buffered saline
7 Study of Epratuzumab in Systemic Lupus Erythematosus Withdrawn NCT00382837 Phase 3 Epratuzumab
8 Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis Unknown status NCT01662973 Phase 1, Phase 2
9 Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE) Completed NCT00997100 Phase 2 paquinimod (ABR-215757)
10 Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus Completed NCT00076752 Phase 2 fludarabine phosphate;cyclophosphamide;methylprednisolone;Diphenhydramine;Mesna
11 Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects Completed NCT01534403 Phase 2
12 Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus Completed NCT01405196 Phase 2
13 Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors Completed NCT00519363 Phase 1, Phase 2 atorvastatin
14 Balancing Lupus Experiences With Stress Strategies Completed NCT01351662 Phase 1, Phase 2
15 Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II Completed NCT01649947 Phase 2 Paclitaxel;Carboplatin;Hydroxychloroquine;Bevacizumab
16 Rituximab Objective Outcome Measures Trial in SLE Recruiting NCT03054259 Phase 2 Rituximab;Methylprednisolone;Normal Saline
17 Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE) Recruiting NCT02338999 Phase 1, Phase 2 Pioglitazone
18 Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Recruiting NCT01988506 Phase 2 Interleukin 2
19 Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC) Terminated NCT01738360 Phase 2 Arsenic trioxide
20 Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus Unknown status NCT00325741 Phase 1
21 Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus Completed NCT01764594 Phase 1
22 Safety Study of AMG 557 in Subjects With Lupus Arthritis Completed NCT01683695 Phase 1 AMG 557;Matching Placebo
23 Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the Blood Completed NCT02306629 Phase 1
24 Omalizumab for Lupus Completed NCT01716312 Phase 1 Omalizumab
25 Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg Completed NCT00705367 Phase 1 Placebo;Abatacept;Abatacept
26 Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus Recruiting NCT02535689 Phase 1 Tofacitinib;Placebo
27 Aerobic Exercise on Improving Sleep in Systemic Lupus Erythematosus. Unknown status NCT02037971
28 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
29 GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus Completed NCT01992666
30 Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus (CLU) Study Completed NCT00342095
31 Effects of Treatment of Chronic Stress in Patients With Lupus Completed NCT00483613
32 Auto-immune Diseases and Quality of Life Completed NCT02855840
33 Magnetic Resonance Spectroscopy, Perfusion, and Diffusion Tensor Imaging in Neuropsychiatric Lupus Completed NCT00730002
34 Walk With Ease Program For Patients With Systemic Lupus Erythematosus Recruiting NCT02631005
35 Acupressure for Fatigue in Systemic Lupus Erythematosus Recruiting NCT03200548
36 OPAM-IA: Using Digital Activity Trackers to Improve Physical Activity in Inflammatory Arthritis Recruiting NCT02554474
37 Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia Recruiting NCT03154385 Rituximab (Mabthera ®) Belimumab (Benlysta ®)
38 Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases Recruiting NCT02925351
39 Improving the Assessment of SLE Disease Activity Enrolling by invitation NCT03144063
40 Dissemination of the Lupus Interactive Navigator Not yet recruiting NCT02950714
41 SSerum/Urinary Monocyte Chemoattractant Protein-1 Level as a Marker for Lupus Nephritis Not yet recruiting NCT03164720
42 Lupus Intervention for Fatigue Trial Not yet recruiting NCT02653287
43 Cardiology Prevention in Systemic Lupus Erythematosus (SLE) Withdrawn NCT00610805

Search NIH Clinical Center for Systemic Lupus Erythematosus 15

Genetic Tests for Systemic Lupus Erythematosus 15

Anatomical Context for Systemic Lupus Erythematosus 15

MalaCards organs/tissues related to Systemic Lupus Erythematosus 15:

39
T Cells, Monocytes, Skin, Lung

Publications for Systemic Lupus Erythematosus 15

Variations for Systemic Lupus Erythematosus 15

Expression for Systemic Lupus Erythematosus 15

Search GEO for disease gene expression data for Systemic Lupus Erythematosus 15.

Pathways for Systemic Lupus Erythematosus 15

GO Terms for Systemic Lupus Erythematosus 15

Sources for Systemic Lupus Erythematosus 15

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....